ClinicalTrials.gg
RecruitingNCT07599371Updated May 20, 2026

A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma

A Phase 1/2 interventional study of Ivoximab 20 mg/kg, ivgtt, Q4W and Temozolomide (TMZ) in Relapsed/Refractory Glioma, sponsored by The First Affiliated Hospital of Zhengzhou University. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Oct 2024, registered Apr 2026).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Planned enrollment
74th of 104
29 · median 41
Started
2024
with 3 others
Phase 1/2
17 of 112
5 open now
Primary completion
2027-10
later than 7 of 17 live
Registered
111th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 74th largest by planned enrollment of the 104 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 in phase 1/2, reaches primary completion later than 7 of the 17 other live ones, and was the 111th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

This study is a prospective, single-arm clinical trial aimed at evaluating the safety and efficacy of ivoximab combined with temozolomide in the treatment of relapsed/refractory glioma. The study plans to enroll 29 patients with relapsed/refractory glioma. After signing informed consent and meeting the inclusion/exclusion criteria through screening, patients will receive treatment with ivoximab combined with temozolomide. Efficacy evaluation will be conducted every two treatment cycles using the Response Assessment in Neuro-Oncology (RANO 2.0) criteria, and treatment will continue until disease progression or intolerance to the combined regimen.

03

Conditions studied

  • Relapsed/Refractory Glioma

Browse trials for

Keywords

  • relapsed/refractory glioma
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • glioma confirmed by histology and clinical imaging; performance status score of 0-1; Expected survival time ≥ 6 months; Adequate organ function, as demonstrated by meeting the following laboratory parameters; For female subjects of , a urine or serum pregnancy test must be performed within 3 days prior to the first dose of study drug (Cycle 1, Day 1), and the result must be negative. If the urine pregnancy test result cannot be confirmed as negative, a serum pregnancy test is required. A female of non-childbearing potential is defined as being for at least one year, or having undergone surgical sterilization or hysterectomy; If there is a risk of pregnancy, all subjects (both male and female) must use measures with a failure rate of less than 1% per year throughout the entire treatment period until 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy).

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of another within 5 years prior to the first dose (excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ); Currently participating in interventional clinical research treatment, or having received other drugs or used investigational devices within 4 weeks prior to the first dose; Prior treatment with , anti-PD-L1, or anti-PD-L2 agents, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.); Receipt of systemic treatment with Chinese patent medicines with anti-tumor indications or immunomodulatory agents (including thymosin, interferon, interleukin, except for local use to control pleural effusion) within 2 weeks prior to the first dose; Active disease requiring systemic treatment (e.g., with disease-modifying agents, , or ) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment; Receipt of systemic glucocorticoid therapy (excluding nasal spray, inhaled, or other topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose; Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted; Known history of allogeneic organ transplantation (except corneal transplantation) or hematopoietic stem cell transplantation; Known allergy to any drug used in this study; Presence of factors affecting oral administration of temozolomide (e.g., inability to swallow, intestinal obstruction, etc.); Failure to fully recover from toxicity and/or complications caused by any previous intervention prior to the start of treatment (i.e., ≤ Grade 1 or return to baseline, excluding fatigue or alopecia); Known history of (HIV) infection (i.e., HIV 1/2 antibody positive); Untreated active (defined as HBsAg positive with detectable HBV-DNA copy number above the of the testing center's laboratory); Subjects with active virus (HCV) infection (HCV antibody positive and HCV-RNA level above the lower limit of detection); Receipt of a within 30 days prior to the first dose (Cycle 1, Day 1); Note: Inactivated influenza vaccines administered by injection for seasonal influenza are permitted within 30 days prior to the first dose; however, intranasal live attenuated influenza vaccines are not permitted.

Pregnant or breastfeeding women; Presence of any severe or uncontrolled systemic disease; Evidence of medical history or disease, treatment, or abnormal laboratory values that may interfere with the study results or prevent the subject from fully participating in the study, or other conditions deemed by the investigator as unsuitable for enrollment, including potential risks that the investigator believes would make participation in this study inappropriate.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (estimated)

Study arms

  • Experimental
    ivoximab combined with temozolomide

    Ivoximab 20 mg/kg, ivgtt, Q4W; Temozolomide 150 mg/m², D1-D5, P.O., Q4W.

    Drug: Ivoximab 20 mg/kg, ivgtt, Q4W · Drug: Temozolomide (TMZ)

Interventions

  • DrugIvoximab 20 mg/kg, ivgtt, Q4W

    We have not found any treatment recorded as this combination

  • DrugTemozolomideStudies of TemozolomideTemozolomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Temozolomide 150 mg/m², D1-D5, P.O., Q4W

06

What researchers measure

Primary outcomes

  1. Objective response rate

    Objective response rate

    Time frame: From enrollment to the end of treatment (weeks),which will be taken at 6 months, 1 year from the start of this combination of treatment.

Secondary outcomes

  1. Overall survival

    from the start of this treatment to death

    Time frame: up to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 45 non-industry phase 1/2 interventional studies under Glioma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 104. This study's planned 36 months is below that.

Counting every sponsor, half of 71 studies reached it within 66 months; a quarter within 48 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 20, 2026
StartActual
Oct 10, 2024
Primary completionEst.
Oct 10, 2027
CompletionEst.
Oct 10, 2028
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599371
Responsible party
Chang Su (PhD/Attending Physician, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
May 20, 2026
Start date
Oct 10, 2024
Primary completion
Oct 10, 2027 (estimated)
Completion
Oct 10, 2028 (estimated)
Last update
May 20, 2026

Study contacts

Chang Su, PhD
Contact
suchang0720@zzu.edu.cn
8615890620692

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion